Unknown

Dataset Information

0

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naive Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.


ABSTRACT: The impact of ribavirin (RBV) dosage on sustained virologic response (SVR) rates remains elusive in hepatitis C virus genotype 2 (HCV-2) rapid responders receiving 16 weeks of peginterferon (Peg-IFN) plus RBV. Treatment-naïve HCV-2 patients with rapid virologic response (RVR) received Peg-IFN alfa-2a 180??g/week plus weight-based RBV (1,000 or 1,200?mg/day; cut-off body weight: 75?kg) for 6 weeks, and then randomly received Peg-IFN alfa-2a 180??g/week plus weight-based (1,000 or 1,200?mg/day; n?=?247) or flat-dose (800?mg/day; n?=?246) RBV for additional 10 weeks. The primary endpoint was SVR24. Patients receiving weight-based and flat-dose RBV therapies had comparable SVR24 rates (93.5% versus 91.9%, P?=?0.49). The risk differences (RDs) of SVR24 receiving weight-based and flat-dose RBV arms were 7.1% [95% CI: 0.7% to 13.6%] in males, and -5.8% [95% CI: -12.1% to 0.5%] in females (interaction P?=?0.01). The SVR24 rate was higher in males receiving ?13?mg/kg/day than those receiving <13?mg/kg/day (96.3% versus 85.1%, P?=?0.001). In conclusion, Peg-IFN alfa-2a plus weight-based or flat-dose RBV for 16 weeks provides comparable SVR24 rates in treatment-naïve HCV-2 rapid responders. However, males should receive weight-based RBV to achieve a high SVR24 rate.

SUBMITTER: Liu CH 

PROVIDER: S-EPMC4606559 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.

Liu Chen-Hua CH   Huang Chung-Feng CF   Liu Chun-Jen CJ   Dai Chia-Yen CY   Huang Jee-Fu JF   Lin Jou-Wei JW   Liang Cheng-Chao CC   Yang Sheng-Shun SS   Lin Chih-Lin CL   Su Tung-Hung TH   Yang Hung-Chih HC   Chen Pei-Jer PJ   Chen Ding-Shinn DS   Chuang Wan-Long WL   Kao Jia-Horng JH   Yu Ming-Lung ML  

Scientific reports 20151015


The impact of ribavirin (RBV) dosage on sustained virologic response (SVR) rates remains elusive in hepatitis C virus genotype 2 (HCV-2) rapid responders receiving 16 weeks of peginterferon (Peg-IFN) plus RBV. Treatment-naïve HCV-2 patients with rapid virologic response (RVR) received Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000 or 1,200 mg/day; cut-off body weight: 75 kg) for 6 weeks, and then randomly received Peg-IFN alfa-2a 180 μg/week plus weight-based (1,000 or 1,200 mg/day; n   ...[more]

Similar Datasets

| S-EPMC3910820 | biostudies-literature
| S-EPMC4929089 | biostudies-literature
| S-EPMC4806200 | biostudies-literature
| S-EPMC1860092 | biostudies-literature
| S-EPMC4318982 | biostudies-literature
| S-EPMC4805724 | biostudies-literature
| S-EPMC4486927 | biostudies-literature
| S-EPMC5066958 | biostudies-literature
| S-EPMC3897323 | biostudies-literature
| S-EPMC3736350 | biostudies-literature